Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

VernacularTitle:厄洛替尼治疗老年晚期非小细胞肺癌的临床观察
Author: YANG YANXIA ¹ ; WU YONGJUAN ; HUA YUNQI ; YUAN HAIQING
Author Information

1. 内蒙古包头市肿瘤医院
Keywords: Erlotinib; Lung neoplasms; Chemotherapy
From: Chinese Journal of Lung Cancer 2009;12(7):789-791
CountryChina
Language:Chinese
Abstract: Background and objective About 80% lung cancer is non-small cell lung cancer (NSCLC) and more than 7096 are in advanced stage. "lhe aim of this study is to evaluate the clinical efficacy and the side effects of erlotinib in the treat-ment of elderly patients with advanced non-small cell lung cancer. Methods Twenty-nine patients with advanced non-small cell lung cancer were treated with erlotinib 150 mg/d, then the adverse reaction and clinical efficacy were recorded during 3 months. Results Total 29 patients were evaluated for efficacy. The total rate of effect was 20.69%, including I case CR, 5 cases PR, 9 cases SD and 14 cases PD. We compared the effective rate of stage Ⅲwith Ⅳ. There were no significant difference between the effec-tive rate of stageⅢand IV (P=0.337). The main side effects were rash (37.93%), diarrhea (17.24%) and vomiting (6.9%) and most side effects were grade Ⅰ and Ⅱ. Conclusion Erlotinib for elderly patients with advanced non-small cell lung cancer have better effective and less toxic effects and the further clinical study should be warranted.